HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MERCK PROSCAR FOR BALDNESS WILL ENTER PHASE III IN LATE 1994,

This article was originally published in The Rose Sheet

Executive Summary

MERCK PROSCAR FOR BALDNESS WILL ENTER PHASE III IN LATE 1994, "once the lowest effective dose is established," Merck Exec VP- Science & Technology Edward Scolnick, MD, said at an April 12 securities analysts meeting. Proscar (finasteride), orally administered, "increases growth of new hair compared to the continued loss of hair in placebo treated patients," Scolnick stated. "No prior trial in this field has actually shown the loss of hair in the placebo treated group," he added. Proscar is currently marketed as a treatment for benign prostatic hyperplasia.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS000369

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel